• HOME>
  • Investor Relations>
  • IR News>
  • Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016

IR News

Nov. 04, 2016Print(PDF/95KB)R&D

Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; "Sumitomo Dainippon Pharma") announced today that clinical data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 3 to 6, 2016.

Planned poster sessions include:

1. Abstract #4335, [637. Myelodysplastic Syndromes―Clinical Studies: Poster III]

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

Presenter: S. Miyakoshi (Department of Hematology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan)

Monday, December 5 from 6:00 p.m. - 8:00 p.m. (local time), Hall GH

The abstract is now available on the official website of ASH

(URL: https://ash.confex.com/ash/2016/webprogram/Paper89176.html)

【Highlights of the abstract】

  • In phase 1 portion, azacitidine (the first-line treatment option) failure higher-risk (7 patients) and transfusion-dependent lower-risk (5 patients) MDS patients (total 12 patients) were enrolled in 3.5 or 10.5 mg/body cohorts. Safety and tolerability were evaluated, and delayed type hypersensitivity (DTH), WT1-specific CTL induction and expression of WT1 mRNA in peripheral blood and bone marrow cells were also examined.
  • DSP-7888 was well-tolerated in MDS patients and dose-dependent toxicity was not observed except for ISR, although ISR was observed in all patients.
  • Disease control rate (PR+SD) was observed in 66.6 % and CTL induction, one of the secondary clinical activities, was observed in 50% of the 12 evaluable patients.

2. Abstract #4715, [802. Chemical Biology and Experimental Therapeutics: Poster III]

DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1

Note: This data is non-clinical evaluation.

Presenter: M. Goto (DSP Cancer Institute, Sumitomo Dainippon Pharma Co., Ltd., Japan)

Monday, December 5 from 6:00 p.m. - 8:00 p.m. (local time), Hall GH

The abstract is now available on the official website of ASH

(URL: https://ash.confex.com/ash/2016/webprogram/Paper89006.html)

Reference Information (DSP-7888):

DSP-7888 is an investigational cancer peptide vaccine containing the peptides which induce WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes and helper T cells. DSP-7888 induces the WT1 specific cytotoxic T lymphocytes (CTLs), which attack WT1-expressing cancerous cells found in various types of hematologic and solid cancers. By adding a helper T cell-inducing peptide, improved efficacy over that observed with a killer peptide alone treatment regimen may be achieved.
A phase 2 study in patients with MDS who had received and not responded to azacitidine, and a phase 2 study in pediatric patients with relapsed or refractory high grade glioma are currently ongoing in Japan. A phase 1 study in patients with solid tumors and hematologic malignancies is ongoing in the U.S.